Short course
Valuation of Innovative Drugs
Date: Sunday 12 November, 2023
Time: 13:00 – 17:00
Speaker: Fred W. Sorenson
ISPOR forum
EU HTA Regulation HTA-R: How is Italy moving
Date: Tuesday 14 November, 2023
Time: 15:15 – 15:45
Speaker: Patrizia Berto
Exhibit hall theater
How to Prepare for JCA in Local Health Systems? Ensuring HTA, Payer and Industry Readiness to Accelerate Patient Access to Innovation
Date: Monday 13 November, 2023
Time: 15:15 – 15:45
Moderator: Herbert Altmann, head of market access, pricing and reimbursement for PharmaLex (part of Cencora)
Panelists:
Emer Fogarty, Lead on HTA Methodology and Guidelines at NCPE
Matias Olsen, Public Affairs and Policy Manager for EUCOPE
Podium session
The Dutch Lock Procedure for Reimbursement Works as Intended
Date: Monday 13 November, 2023
Time: 11:00 – 11:15
Speakers: Jennifer Boer, Wouter van Straaten, Lieke Boonen
Don't miss our poster presentations during ISPOR Europe 2023:
We're excited to share groundbreaking research at ISPOR Europe! Our research covers everything from the most critical challenges facing healthcare and the upcoming EU Joint Clinical Assessment (JCA) to showcasing groundbreaking solutions and the latest advancements in HEOR. We are incredibly proud to contribute to the conversation and share our findings. Don't miss out on this opportunity to join us and be a part of the discussion on addressing these critical issues.
Resource Center
European Joint Clinical Assessment (JCA)
Live Webinar: November 28 | 10:00AM ET
Patients at the center: Ensuring EU JCA embraces the patients’ voice in their frameworks and decision-making
Catch up on the latest edition of HTA Quarterly
HTA Quarterly | Winter 2023
Navigating the way to the new EU JCA—Are biopharma companies, HTA bodies, patients, and clinicians sufficiently prepared?
The interim period between the closure of the European Network for Health Technology Assessment 21 (EUnetHTA 21) and the full application of the Health Technology Assessment Regulation (HTAR) has begun. Is sufficient guidance available for biopharma companies, health technology assessment (HTA) bodies, patients, and clinicians, or do uncertainties remain?
HTA Quarterly | Winter 2023
How NICE there’s an app for that!
In 2020, there were more than 300,000 healthcare apps available around the world. The sheer number of apps available creates substantial barriers to regulating their use, and the evidence base is scant; so, how do healthcare payers assess the value of an app and decide what and which to pay for?
HTA Quarterly | Winter 2023
The more things change, the more they stay the same? Reviewing ICER's revised value assessment framework
Additional thought-leadership on HTA and global market access
